13G Filing: James E. Flynn and Biocryst Pharmaceuticals Inc (BCRX)

Page 4 of 14

Page 4 of 14 – SEC Filing

CUSIP No.

09058V103

13G Page 4
of 11 Pages
1.

NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Partners,
L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)

(b) ☒

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

 

 NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

1,336,816 (3)

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

1,336,816 (3)

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,336,816 (3)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES*

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

1.66%

12.

TYPE OF REPORTING PERSON*

PN

(3) Includes options to purchase 220,000 shares of common stock.

Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)

Page 4 of 14